Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ECE1 | P42892 | 3/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | CCR2 | P41597 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL926034 | 0.86 | ABCB1 (0.46) | F10ECE1ABCB1CCR2FSCN1 | |
| SCHEMBL1051931 | 0.83 | F10 (0.43) | F10MAPTKDM4EALDH1A1CYP1A2 | |
| SCHEMBL926868 | 0.80 | ABCB1 (0.45) | F10MAPTECE1ABCB1CCR2 | |
| SCHEMBL2898536 | 0.79 | ABCB1 (0.47) | F10MAPTKDM4ECYP1A2CYP3A4 | |
| SCHEMBL1050259 | 0.78 | F10 (0.42) | F10ECE1ABCB1CCR2FSCN1 | |
| SCHEMBL1053385 | 0.78 | F10 (0.46) | F10MAPTSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL926660 | 0.78 | MAOB (0.47) | F10ECE1ABCB1CCR2FSCN1 | |
| SCHEMBL2898360 | 0.78 | SCD (0.45) | F10MAPTALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL4406277 | 0.78 | RAB9A (0.55) | MAPTCYP1A2CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL1049577 | 0.78 | NPC1 (0.48) | F10MAPTKDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2235014-B1 | BICYCLIC DERIVATIVES OF AZABICYCLIC CARBOXAMIDES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2013-10-09 | — | — | EP | claimed |
| US-8299114-B2 | Bicyclic derivatives of azabicyclic carboxamides, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2012-10-30 | — | — | US | claimed |
| US-20110009400-A1 | BICYCLIC DERIVATIVES OF AZABICYCLIC CARBOXAMIDES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | claimed |
| US-8604050-B2 | Bicyclic derivatives of azabicyclic carboxamides, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-12-10 | — | — | US | disclosed |
| EP-2235014-B1 | BICYCLIC DERIVATIVES OF AZABICYCLIC CARBOXAMIDES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2013-10-09 | — | — | EP | disclosed |
| US-8299114-B2 | Bicyclic derivatives of azabicyclic carboxamides, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2012-10-30 | — | — | US | disclosed |
| US-20120252837-A1 | BICYCLIC DERIVATIVES OF AZABICYCLIC CARBOXAMIDES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-10-04 | — | — | US | disclosed |
| US-20110009400-A1 | BICYCLIC DERIVATIVES OF AZABICYCLIC CARBOXAMIDES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009400-A1 | BICYCLIC DERIVATIVES OF AZABICYCLIC CARBOXAMIDES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | XDH, NQO2, HDAC1 | F10 1624/4885MAPT 4270/4885KDM4E 377/4885 |
| US-20120252837-A1 | BICYCLIC DERIVATIVES OF AZABICYCLIC CARBOXAMIDES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | XDH, NQO2, HDAC1 | F10 1624/4885MAPT 4270/4885KDM4E 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.